BPC-157 has attracted significant attention in the research community over the past two decades. Originally identified as a fragment of a protein found in human gastric juice, it has since been synthesised and studied across a broad range of tissue types and research models. This article covers the key facts researchers need before working with the compound.
What Is BPC-157?
BPC-157 stands for Body Protection Compound 157. It is a synthetic pentadecapeptide, meaning it consists of 15 amino acids, with the molecular formula C62H98N16O22 and a molecular weight of approximately 1419.5 Da. The compound was derived from a stable gastric pentadecapeptide found in human gastric juice, known to exhibit cytoprotective properties in the gastrointestinal tract.
Unlike many synthetic peptides, BPC-157 is relatively stable under physiological conditions. Its resistance to proteolytic degradation in gastric environments is thought to contribute to its persistence in biological models, which is one reason it has become a widely used compound in pre-clinical research settings.
Primary Areas of Research
Gastrointestinal and Mucosal Studies
Given its origin from gastric juice protein BPC, researchers have extensively studied its role in gastric and intestinal mucosal healing. Pre-clinical models have investigated its cytoprotective effects on the gastric mucosa, including protection against ethanol-induced lesions and NSAID-associated damage. The compound appears to interact with the nitric oxide (NO) system, which plays a central role in mucosal blood flow regulation and tissue repair.
Musculoskeletal Tissue Research
A significant body of pre-clinical work has examined BPC-157 in the context of tendon, ligament, and muscle repair. Rodent models have demonstrated accelerated healing of transected tendons and ligaments following administration, with proposed mechanisms involving enhanced collagen organisation, increased fibroblast activity, and upregulation of growth factor receptors including VEGF. These findings have made it a compound of considerable interest in musculoskeletal biology.
Neural Tissue Studies
Research has also explored BPC-157 in neural contexts. Studies have investigated its potential neuroprotective properties in models of traumatic brain injury and peripheral nerve damage. The compound's interaction with dopaminergic and serotonergic systems has been documented in rodent models, prompting interest in its role in central nervous system research.
Angiogenesis and Vascular Research
Several studies have examined BPC-157's influence on angiogenic signalling. The compound appears to upregulate VEGF expression and promote the formation of new blood vessels in damaged tissue models. This vascular activity is thought to be one of the central mechanisms underlying its tissue-level effects observed across different organ systems.
BPC-157 Available from Clarix Peptides
HPLC-verified, 99%+ purity. Certificate of Analysis included. Available in 5mg and 10mg. Fast UK dispatch.
Handling and Laboratory Considerations
Supplied Format
BPC-157 is supplied as a lyophilised (freeze-dried) white powder in sealed glass vials. At high purity levels the lyophilised material may appear as an extremely fine powder or a thin translucent film on the vial wall — this is entirely normal and does not indicate a defective product. It is the standard appearance of high-purity lyophilised peptides.
Reconstitution
For in vitro use, BPC-157 is typically reconstituted using bacteriostatic water or sterile 0.9% saline. The standard approach involves allowing the solvent to run slowly down the side of the vial rather than injecting directly onto the powder, which minimises peptide degradation through mechanical disruption. Gentle swirling rather than shaking is recommended during dissolution.
Storage
Lyophilised BPC-157 should be stored at minus 20 degrees Celsius for long-term preservation. For short-term active use, storage at 2 to 8 degrees Celsius in a sealed, desiccated container is appropriate. Once reconstituted, solutions should be kept refrigerated at 4 degrees and used within 28 to 30 days. Repeated freeze-thaw cycles should be avoided as they degrade peptide integrity over time.
Purity and Quality Considerations
The quality of BPC-157 used in research directly affects the reliability of experimental results. Key specifications to look for when sourcing the compound include purity by HPLC (high-performance liquid chromatography), confirmation of peptide identity by mass spectrometry, and the presence of a Certificate of Analysis (COA) from an accredited third-party laboratory. Purity below 95% introduces significant uncertainty into research outcomes.
At Clarix Peptides, every batch of BPC-157 is independently tested by an accredited UK laboratory before dispatch. The COA covering purity and mass spec confirmation is available for download with each order.
